Jump to content

Gestodene

From Wikipedia, the free encyclopedia
(Redirected from Avadene)
Gestodene
Clinical data
Trade namesFemodene, Femodette, Gynera, Harmonet, Meliane, Minesse, Minulet, others
Other namesGSD; SHB-331; δ15-Norgestrel; 15-Dehydronorgestrel; 17-hydroxy-18a-homo-19-nor-17α-pregna-4,15-dien-20-yn-3-one; 17α-Ethynyl-18-methyl-19-nor-δ15-testosterone; 17α-Ethynyl-18-methylestra-4,15-dien-17β-ol-3-one; 13β-Ethyl-18,19-dinor-17α-pregna-4,15-dien-20-yn-17β-ol-3-one
AHFS/Drugs.comInternational Drug Names
Pregnancy
category
  • X
Routes of
administration		By mouth
Drug classProgestogen; Progestin
ATC code
Legal status
Legal status
  • In general: ℞ (Prescription only)
Pharmacokinetic data
Bioavailability96% (87–111%)[1][2][3]
Protein binding98% (64% to SHBGTooltip sex hormone-binding globulin, 34% to albumin, 2% free)[4]
MetabolismLiver (reduction, hydroxylation)[4]
Elimination half-life12–15 hours[2][4]
ExcretionUrine
Identifiers
  • (8R,9S,10R,13S,14S,17R)-13-ethyl-17-ethynyl-17-hydroxy-1,2,6,7,8,9,10,11,12,14-decahydrocyclopenta[a]phenanthren-3-one
CAS Number
PubChem CID
DrugBank
ChemSpider
UNII
KEGG
ChEBI
ChEMBL
CompTox Dashboard (EPA)
ECHA InfoCard100.056.478 Edit this at Wikidata
Chemical and physical data
FormulaC21H26O2
Molar mass310.437 g·mol−1
3D model (JSmol)
Melting point197.9 °C (388.2 °F)
  • O=C4\C=C3/[C@@H]([C@H]2CC[C@]1([C@@H](/C=C\[C@]1(C#C)O)[C@@H]2CC3)CC)CC4
  • InChI=1S/C21H26O2/c1-3-20-11-9-17-16-8-6-15(22)13-14(16)5-7-18(17)19(20)10-12-21(20,23)4-2/h2,10,12-13,16-19,23H,3,5-9,11H2,1H3/t16-,17+,18+,19-,20-,21-/m0/s1 checkY
  • Key:SIGSPDASOTUPFS-XUDSTZEESA-N checkY
  (verify)

Gestodene, sold under the brand names Femodene and Minulet among others, is a progestin medication which is used in birth control pills for women.[5][6] It is also used in menopausal hormone therapy.[7] The medication is available almost exclusively in combination with an estrogen.[8] It is taken by mouth.[6][9]

Side effects of the combination of an estrogen and gestodene include menstrual irregularities, headaches, nausea, breast tenderness, mood changes, and others.[citation needed] Gestodene is a progestin, or a synthetic progestogen, and hence is an agonist of the progesterone receptor, the biological target of progestogens like progesterone.[10][11] It has weak androgenic activity, weak antimineralocorticoid activity, and weak glucocorticoid activity.[10][11]

Gestodene was discovered in 1975 and was introduced for medical use, specifically in birth control pills, in 1987.[4][12] It was subsequently introduced for use in menopausal hormone therapy as well.[7][8] Gestodene is sometimes referred to as a "third-generation" progestin.[13] It is marketed in birth control pills widely throughout the world, whereas it is available for use in menopausal hormone therapy only a few countries.[8][7] Gestodene is not approved in the United States.[14][15]

Medical uses

[edit]

Gestodene is neutral in terms of androgenic activity, meaning that contraceptive pills containing gestodene do not exhibit the androgenic side effects (e.g., acne, hirsutism) sometimes associated with second-generation contraceptive pills such as those containing levonorgestrel.[16]

The estrogen dosage in third-generation contraceptive pills (including those containing gestodene) is lower than that in second-generation oral contraceptives, reducing the likelihood of weight gain, breast tenderness, and migraine.[17]

Third-generation oral contraceptives are also suitable for use in patients with diabetes or lipid disorders because they have minimal impact on blood glucose levels and the lipid profile.[18]

Gestodene is also available in combination with estradiol for use in menopausal hormone therapy.[7][8]

Available forms

[edit]

Contraceptive products containing gestodene include:

  • Melodene-15, Mirelle, and Minesse which contain 15 μg of ethinylestradiol and 60 μg of gestodene;
  • Meliane, Sunya, Femodette, and Millinette 20/75 which contain 20 μg of ethinylestradiol and 75 μg of gestodene; and
  • Gynera, Minulet, Femoden, Femodene, Katya and Millinette 30/75 which contain 30 μg of ethinylestradiol and 75 μg of gestodene.[19]

Contraindications

[edit]
See also: Progestin § Contraindications

Side effects

[edit]
See also: Progestin § Side effects

Women who take oral contraceptives containing gestodene are 5.6 times as likely to develop venous thromboembolism than women who do not take any contraceptive pill, and 1.6 times as likely to develop venous thromboembolism compared to women taking oral contraceptives containing levonorgestrel.[20]

Overdose

[edit]
See also: Progestin § Overdose

Contraindications

[edit]
See also: Progestin § Interactions

Pharmacology

[edit]

Pharmacodynamics

[edit]

Gestodene is a highly potent progestogen, and also possesses weak androgenic, antimineralocorticoid, and glucocorticoid activity.[9][10][11] Due to its progestogenic activity, it has antigonadotropic and functional antiestrogenic effects.[9] The medication has little or no estrogenic and no antiandrogenic activity.[9]

Relative affinities (%) of gestodene
Compound PRTooltip Progesterone receptor ARTooltip Androgen receptor ERTooltip Estrogen receptor GRTooltip Glucocorticoid receptor MRTooltip Mineralocorticoid receptor SHBGTooltip Sex hormone-binding globulin CBGTooltip Corticosteroid binding globulin
Gestodene 90–432 85 0 27–38 97–290 40 0
Notes: Values are percentages (%). Reference ligands (100%) were promegestone for the PRTooltip progesterone receptor, metribolone for the ARTooltip androgen receptor, E2 for the ERTooltip estrogen receptor, DEXATooltip dexamethasone for the GRTooltip glucocorticoid receptor, aldosterone for the MRTooltip mineralocorticoid receptor, DHTTooltip dihydrotestosterone for SHBGTooltip sex hormone-binding globulin, and cortisol for CBGTooltip Corticosteroid-binding globulin. Sources: [9]

Progestogenic activity

[edit]

Gestodene is a progestogen, and hence is an agonist of the progesterone receptor.[9] Based on the dosage necessary to inhibit ovulation in women, gestodene is the most potent of all of the currently used oral contraceptive progestogens.[21][22][23] The oral dosage of gestodene required for ovulation inhibition is 30 or 40 μg per day.[22][24] This is about 10,000 times lower than the oral dosage of progesterone required to inhibit ovulation (300 mg/day).[11][9] A dosage of gestodene of 75 μg/day is used in contraceptives.[23]

Androgenic activity

[edit]

Gestodene has relatively high affinity for the androgen receptor (AR), with twice that of levonorgestrel (which is known to be one of the more androgenic 19-nortestosterone derivatives).[25] However, the ratio of progestogenic to androgenic effects of gestodene is distinctly higher than that of levonorgestrel, and the increase in sex hormone-binding globulin (SHBG) levels (a marker of androgenicity) produced by oral contraceptives containing gestodene is slightly less than that produced by oral contraceptives containing desogestrel (which is known to be one of the more weakly androgenic 19-nortestosterone derivatives).[25] In addition, no difference in acne incidence has been observed with oral contraceptives containing gestodene and oral contraceptives containing desogestrel.[26] Gestodene may also act to some extent as a 5α-reductase inhibitor.[9][25] Taken together, like desogestrel, gestodene appears to have a low potential for androgenic effects.[25]

Glucocorticoid activity

[edit]

Gestodene has relatively high affinity for the glucocorticoid receptor, about 27% of that of the corticosteroid dexamethasone.[9] It has weak glucocorticoid activity.[9]

Glucocorticoid activity of selected steroids in vitro
Steroid Class TRTooltip Thrombin receptor (↑)a GRTooltip glucocorticoid receptor (%)b
Dexamethasone Corticosteroid ++ 100
Ethinylestradiol Estrogen – 0
Etonogestrel Progestin + 14
Gestodene Progestin + 27
Levonorgestrel Progestin – 1
Medroxyprogesterone acetate Progestin + 29
Norethisterone Progestin – 0
Norgestimate Progestin – 1
Progesterone Progestogen + 10
Footnotes: a = Thrombin receptor (TR) upregulation (↑) in vascular smooth muscle cells (VSMCs). b = RBATooltip Relative binding affinity (%) for the glucocorticoid receptor (GR). Strength: – = No effect. + = Pronounced effect. ++ = Strong effect. Sources: [27]

Antimineralocorticoid activity

[edit]

Gestodene has very high affinity for the mineralocorticoid receptor (MR), but has only a relatively weak antimineralocorticoid effect that is comparable to that of progesterone.[25]

Other activities

[edit]

Although gestodene does not bind to the estrogen receptor itself, the drug may have some estrogenic activity, and this would appear to be mediated by its weakly estrogenic metabolites 3β,5α-tetrahydrogestodene and to a lesser extent 3α,5α-tetrahydrogestodene.[28]

Gestodene binds to SHBG with relatively high affinity; it is 75% bound to the protein in circulation.[11][25]

Gestodene shows some inhibition of cytochrome P450 enzymes in vitro, and has greater potency in this action compared to other progestins (IC50Tooltip half-maximal inhibitory concentration = 5.0 μM).[9][1] The medication also shows some inhibition of 5α-reductase in vitro (14.5% at 0.1 μM, 45.9% at 1.0 μM).[9] Like with cytochrome P450 inhibition, gestodene was more potent in this action compared to other progestins, including desogestrel and levonorgestrel.[9][25]

Pharmacokinetics

[edit]

The oral bioavailability of gestodene has been found to range from 87 to 111%, with a mean of 96%.[1][2][3][4] Unlike other third-generation progestins like desogestrel and norgestimate, gestodene is not a prodrug.[1][29] Peak levels of gestodene occur within 1 to 4 hours after an oral dose, but usually within 1 to 2 hours.[1] The plasma protein binding of gestodene is 98%.[4] It is bound 64% to sex hormone-binding globulin and 34% to albumin, with 2% circulating freely.[4] Gestodene is metabolized in the liver via reduction of the δ4-3-keto group to form 3,5-tetrahydrogenated metabolites (major pathway) and via hydroxylation at the C1, C6, and C11 positions (substantial).[4][1] In spite of differing from it only by the presence of an additional double bond between the C15 and C16 positions, gestodene is not metabolized into levonorgestrel in the body.[1] The biological half-life of gestodene is 12 to 15 hours.[2][4] Gestodene is eliminated 50% in urine and 33% in feces.[1] Of gestodene excreted in urine, 25% is in the form of glucuronide conjugates, 35% is as sulfate conjugates, and 25% is unconjugated.[1]

Chemistry

[edit]
See also: List of progestogens

Gestodene, also known as 17α-ethynyl-18-methyl-19-nor-δ15-testosterone, as well as 17α-ethynyl-18-methylestra-4,15-dien-17β-ol-3-one or 13β-ethyl-18,19-dinor-17α-pregna-4,15-dien-20-yn-17β-ol-3-one, is a synthetic estrane steroid and a derivative of testosterone.[5][8] It is more specifically a derivative of norethisterone (17α-ethynyl-19-nortestosterone) and is a member of the gonane (18-methylestrane) subgroup of the 19-nortestosterone family of progestins.[30] Gestodene is almost identical to levonorgestrel in terms of chemical structure, differing only in having an additional double bond between the C15 and C16 positions, and for this reason is also known as δ15-norgestrel or as 15-dehydronorgestrel.[31][32]

History

[edit]

Gestodene was first synthesized in 1975.[4] It was introduced for medical use, specifically in combination with ethinylestradiol as a combined oral contraceptive, in 1987.[12] The medication was introduced for use in menopausal hormone therapy in combination with estradiol in some countries such as in Europe and Latin America years later.[7][8]

Society and culture

[edit]

Generic names

[edit]

Gestodene is the generic name of the drug and its INNTooltip International Nonproprietary Name, USANTooltip United States Adopted Name, BANTooltip British Approved Name, and DCFTooltip Dénomination Commune Française.[5][6][8] It is also known by its developmental code name SHB-331.[5][8]

Brand names

[edit]

Gestodene is marketed as a contraceptive in combination with ethinylestradiol under a variety of brand names including Femoden, Femodene, Femodette, Gynera, Harmonet, Lindynette, Logest, Meliane, Millinette, Minesse, Minulet, Mirelle, and Triadene as well as many others.[8] It is marketed for use in menopausal hormone therapy in combination with estradiol under the brand names Avaden, Avadene, and Convaden.[7][8]

Availability

[edit]

Gestodene is marketed in the United Kingdom, Ireland, elsewhere throughout Europe, South Africa, Australia, Latin America, Asia, and elsewhere in the world.[8] It is not listed as being marketed in the United States, Canada, New Zealand, Japan, South Korea, India, or certain other countries.[8] Gestodene is marketed for use specifically in menopausal hormone therapy only in a few countries, including Colombia, Ecuador, Mexico, Peru, and Portugal.[8]

References

[edit]
  1. ^ a b c d e f g h i Mishell DR (10 November 1999). Progestins and Antiprogestins in Clinical Practice. Taylor & Francis. pp. 133–151. ISBN 978-0-8247-8291-7.
  2. ^ a b c d Stanczyk FZ (2002). "Pharmacokinetics and potency of progestins used for hormone replacement therapy and contraception". Rev Endocr Metab Disord. 3 (3): 211–24. doi:10.1023/A:1020072325818. PMID 12215716. S2CID 27018468.
  3. ^ a b Fotherby K (August 1996). "Bioavailability of orally administered sex steroids used in oral contraception and hormone replacement therapy". Contraception. 54 (2): 59–69. doi:10.1016/0010-7824(96)00136-9. PMID 8842581.
  4. ^ a b c d e f g h i j Kuhl H, Jung-Hoffmann C, Wiegratz I (December 1995). "Gestodene-containing contraceptives". Clin Obstet Gynecol. 38 (4): 829–40. doi:10.1097/00003081-199538040-00018. PMID 8616979.
  5. ^ a b c d Elks J (14 November 2014). The Dictionary of Drugs: Chemical Data: Chemical Data, Structures and Bibliographies. Springer. pp. 595–. ISBN 978-1-4757-2085-3.
  6. ^ a b c Morton IK, Hall JM (31 October 1999). Concise Dictionary of Pharmacological Agents: Properties and Synonyms. Springer Science & Business Media. pp. 132–. ISBN 978-0-7514-0499-9.
  7. ^ a b c d e f "Estradiol/gestodene - Bayer Healthcare Pharmaceuticals - AdisInsight". adisinsight.springer.com.
  8. ^ a b c d e f g h i j k l m "Gestodene - Drugs.com". drugs.com.
  9. ^ a b c d e f g h i j k l m Kuhl H (2005). "Pharmacology of estrogens and progestogens: influence of different routes of administration" (PDF). Climacteric. 8 (Suppl 1): 3–63. doi:10.1080/13697130500148875. PMID 16112947. S2CID 24616324.
  10. ^ a b c Fuhrmann U, Slater EP, Fritzemeier KH (January 1995). "Characterization of the novel progestin gestodene by receptor binding studies and transactivation assays". Contraception. 51 (1): 45–52. doi:10.1016/0010-7824(94)00003-F. PMID 7750284.
  11. ^ a b c d e Schindler AE, Campagnoli C, Druckmann R, Huber J, Pasqualini JR, Schweppe KW, Thijssen JH (December 2003). "Classification and pharmacology of progestins". Maturitas. 46 (Suppl 1): S7–S16. doi:10.1016/j.maturitas.2003.09.014. PMID 14670641.
  12. ^ a b Runnebaum BC, Rabe T, Kiesel L (6 December 2012). Female Contraception: Update and Trends. Springer Science & Business Media. pp. 13–. ISBN 978-3-642-73790-9.
  13. ^ Carp HJ (9 April 2015). Progestogens in Obstetrics and Gynecology. Springer. p. 112. ISBN 978-3-319-14385-9.
  14. ^ Becker KL (2001). Principles and Practice of Endocrinology and Metabolism. Lippincott Williams & Wilkins. pp. 1024–. ISBN 978-0-7817-1750-2.
  15. ^ Jiang Q, He W (25 May 2016). Benefit-Risk Assessment Methods in Medical Product Development: Bridging Qualitative and Quantitative Assessments. CRC Press. pp. 135–. ISBN 978-1-4822-5937-7.
  16. ^ "Anti-androgen therapy | DermNet NZ". 26 October 2023.
  17. ^ Festin M (2006). "Progestogens in combined oral contraceptives for contraception". The WHO Reproductive Health Library.
  18. ^ Cerel-Suhl SL, Yeager BF (November 1999). "Update on oral contraceptive pills". American Family Physician. 60 (7): 2073–2084. PMID 10569509.
  19. ^ "prospecto" (PDF). Archived from the original (PDF) on 2011-07-22. Retrieved 2011-04-20.
  20. ^ Lidegaard Ø, Nielsen LH, Skovlund CW, Skjeldestad FE, Løkkegaard E (October 2011). "Risk of venous thromboembolism from use of oral contraceptives containing different progestogens and oestrogen doses: Danish cohort study, 2001-9". BMJ. 343: d6423. doi:10.1136/bmj.d6423. PMC 3202015. PMID 22027398.
  21. ^ Skouby SO (15 July 1997). Clinical Perspectives on a New Gestodene Oral Contraceptive Containing 20μg of Ethinylestradiol. CRC Press. pp. 19–. ISBN 978-1-85070-786-8.
  22. ^ a b Benagiano G, Primiero FM, Farris M (2004). "Clinical profile of contraceptive progestins". Eur J Contracept Reprod Health Care. 9 (3): 182–93. doi:10.1080/13625180400007736. PMID 15697108. S2CID 36352864.
  23. ^ a b Shoupe D, Haseltine FP (6 December 2012). Contraception. Springer Science & Business Media. pp. 62–. ISBN 978-1-4612-2730-4.
  24. ^ Schindler AE, Campagnoli C, Druckmann R, Huber J, Pasqualini JR, Schweppe KW, Thijssen JH (2008). "Classification and pharmacology of progestins". Maturitas. 61 (1–2): 171–80. doi:10.1016/j.maturitas.2008.11.013. PMID 19434889.
  25. ^ a b c d e f g Stanczyk FZ, Archer DF (April 2014). "Gestodene: a review of its pharmacology, potency and tolerability in combined contraceptive preparations". Contraception. 89 (4): 242–252. doi:10.1016/j.contraception.2013.12.003. PMID 24485094.
  26. ^ Arowojolu AO, Gallo MF, Lopez LM, Grimes DA (July 2012). Arowojolu AO (ed.). "Combined oral contraceptive pills for treatment of acne". The Cochrane Database of Systematic Reviews (7): CD004425. doi:10.1002/14651858.CD004425.pub6. PMC 11437354. PMID 22786490.
  27. ^ Kuhl H (2005). "Pharmacology of estrogens and progestogens: influence of different routes of administration" (PDF). Climacteric. 8 Suppl 1: 3–63. doi:10.1080/13697130500148875. PMID 16112947. S2CID 24616324.
  28. ^ Lemus AE, Zaga V, Santillán R, García GA, Grillasca I, Damián-Matsumura P, Jackson KJ, Cooney AJ, Larrea F, Pérez-Palacios G (2000). "The oestrogenic effects of gestodene, a potent contraceptive progestin, are mediated by its A-ring reduced metabolites". J. Endocrinol. 165 (3): 693–702. doi:10.1677/joe.0.1650693. PMID 10828854.
  29. ^ Lemke TL, Williams DA (2008). Foye's Principles of Medicinal Chemistry. Lippincott Williams & Wilkins. pp. 1316–. ISBN 978-0-7817-6879-5.
  30. ^ Strauss JF, Barbieri RL (2009). Yen and Jaffe's Reproductive Endocrinology: Physiology, Pathophysiology, and Clinical Management. Elsevier Health Sciences. pp. 878–. ISBN 978-1-4160-4907-4.
  31. ^ Ellen JM, Irwin CE (1996). "Primary care management of adolescent sexual behavior". Curr. Opin. Pediatr. 8 (5): 442–8. doi:10.1097/00008480-199610000-00004. PMID 8946122.
  32. ^ Fritz MA, Speroff L (2011). Clinical Gynecologic Endocrinology and Infertility. Lippincott Williams & Wilkins. pp. 966–. ISBN 978-0-7817-7968-5.

Further reading

[edit]
  • Chez RA (May 1989). "Clinical aspects of three new progestogens: desogestrel, gestodene, and norgestimate". Am. J. Obstet. Gynecol. 160 (5 Pt 2): 1296–300. doi:10.1016/S0002-9378(89)80016-X. PMID 2524163.
  • Täuber U, Kuhnz W, Hümpel M (October 1990). "Pharmacokinetics of gestodene and ethinyl estradiol after oral administration of a monophasic contraceptive". Am. J. Obstet. Gynecol. 163 (4 Pt 2): 1414–20. doi:10.1016/0002-9378(90)91358-J. PMID 2220966.
  • London RS (November 1992). "The new era in oral contraception: pills containing gestodene, norgestimate, and desogestrel". Obstet Gynecol Surv. 47 (11): 777–82. doi:10.1097/00006254-199211000-00014. PMID 1436906.
  • Shoupe D (May 1994). "New progestins--clinical experiences: gestodene". Am. J. Obstet. Gynecol. 170 (5 Pt 2): 1562–8. doi:10.1016/S0002-9378(94)05020-9. PMID 8178907.
  • Sobel NB (June 1994). "Progestins in preventive hormone therapy. Including pharmacology of the new progestins, desogestrel, norgestimate, and gestodene: are there advantages?". Obstet. Gynecol. Clin. North Am. 21 (2): 299–319. doi:10.1016/S0889-8545(21)00630-6. PMID 7936546.
  • Kaplan B (1995). "Desogestrel, norgestimate, and gestodene: the newer progestins". Ann Pharmacother. 29 (7–8): 736–42. doi:10.1177/106002809502907-817. PMID 8520092. S2CID 45885232.
  • Wilde MI, Balfour JA (August 1995). "Gestodene. A review of its pharmacology, efficacy and tolerability in combined contraceptive preparations". Drugs. 50 (2): 364–95. doi:10.1016/j.contraception.2013.12.003. PMID 8521763.
  • Kuhl H, Jung-Hoffmann C, Wiegratz I (December 1995). "Gestodene-containing contraceptives". Clin Obstet Gynecol. 38 (4): 829–40. doi:10.1097/00003081-199538040-00018. PMID 8616979.
  • Stanczyk FZ (May 1997). "Pharmacokinetics of the new progestogens and influence of gestodene and desogestrel on ethinylestradiol metabolism". Contraception. 55 (5): 273–82. doi:10.1016/S0010-7824(97)00030-9. PMID 9220223.
  • Szabó L, Nagy K, Godó G (March 1998). "[Experience with gestodene-containing hormonal contraceptive]". Orv Hetil (in Hungarian). 139 (9): 481–5. PMID 9528290.
  • Winkler UH (September 1998). "Effects on hemostatic variables of desogestrel- and gestodene-containing oral contraceptives in comparison with levonorgestrel-containing oral contraceptives: a review". Am. J. Obstet. Gynecol. 179 (3 Pt 2): S51–61. doi:10.1053/ob.1998.v179.a92633. PMID 9753311.
  • Stanczyk FZ, Archer DF (April 2014). "Gestodene: a review of its pharmacology, potency and tolerability in combined contraceptive preparations". Contraception. 89 (4): 242–52. doi:10.1016/j.contraception.2013.12.003. PMID 24485094.
Retrieved from "https://en.wikipedia.org/w/index.php?title=Gestodene&oldid=1255817190"